adenosine monophosphate has been researched along with sulprostone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dovlatova, N; Fox, SC; Heptinstall, S; Johnson, AJ; Latif, ML; Manolopoulos, P; Ralevic, V; White, AE; Wijeyeratne, YD | 1 |
| Dovlatova, N; Espinosa, DI; Fox, SC; Glenn, JR; Gurney, M; Hartman, D; Heptinstall, S; Hermann, D; Johnson, A; Magnusson, O; Manolopoulos, P; May, JA; Stefansson, K; White, AE | 1 |
2 other study(ies) available for adenosine monophosphate and sulprostone
| Article | Year |
|---|---|
Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Animals; Blood Platelets; Cell Adhesion Molecules; Dinoprostone; Humans; Immunoblotting; Microfilament Proteins; Microscopy, Confocal; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Count; Purinergic P2 Receptor Agonists; Rats; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP3 Subtype; Receptors, Purinergic P2; Uridine Diphosphate Glucose | 2008 |
DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease.
Topics: Acrylamides; Adenosine Monophosphate; Aspirin; Atherosclerosis; Blood Platelets; Cells, Cultured; Dinoprostone; Drug Interactions; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP3 Subtype; Receptors, Purinergic P2Y12; Sulfones | 2008 |